What is it about?
What is already known on this topic - Earlier case studies on Rexon-Eye have shown encouraging improvement in subjective and objective dry eye parameters, but they were mostly conducted small scale in Western populations targeting mild to moderate dry eye disease. - What this study adds - In Asian moderate to severe recalcitrant dry eyes treated with Rexon-Eye, inferior cornea staining showed significant improvement compared to placebo, and eyes with worse corneal staining had the greatest improvement in their ocular surface. Rexon-Eye showed subjective improvement in dry eye symptoms in 40%.
Featured Image
Photo by Federico Beccari on Unsplash
Why is it important?
How this study might affect research, practice or policy - Rexon-Eye could be a potential adjunctive treatment option for patients with moderate to severe dry eye disease that is poorly responsive to current treatments.
Perspectives
In Asian moderate to severe recalcitrant dry eyes treated with Rexon-Eye, inferior cornea staining showed significant improvement compared to placebo, and eyes with worse corneal staining had the greatest improvement in their ocular surface. Rexon-Eye showed subjective improvement in dry eye symptoms in 40%.
Prof Louis Tong
National University of Singapore
Read the Original
This page is a summary of: Quantum molecular resonance electrotherapy (Rexon-Eye) for recalcitrant dry eye in an Asian population, Frontiers in Medicine, September 2023, Frontiers,
DOI: 10.3389/fmed.2023.1209886.
You can read the full text:
Contributors
The following have contributed to this page
